Conventional IgG antibodies are powerful tools for many applications. Despite their flexibility, they also encounter limits of feasibility. With their size of 150 kDa they are limited in tissue penetration and less stable when it comes to harsh conditions, such as pH stress, temperature stress or protease rich environments, just to name a few.
Single domain antibodies (e.g. VHH) possess properties which circumvent these limitations. This case study demonstrates the power of YUMAB’s VHH discovery platform by combining in-vivo immunization and in-vitro display.
